UROLOGY

Enhancing overactive bladder care: Expert consensus statements for Hong Kong clinicians

18 Dec 2024

Redefining the management of non-muscle-invasive bladder cancer in one swoop with en bloc resection over standard transurethral resection

06 Aug 2024

Navigating genetic testing in prostate cancer: An insight into the joint HKUA-HKSUO consensus recommendations

31 Aug 2023

Local case sharing: Benefits of early intensification with enzalutamide in mHSPC patients with high volume of disease

05 May 2023

A local case sharing: Enzalutamide optimizes care for mHSPC patients with low-volume disease

30 Dec 2022

The PROfound promise of genomics in mCRPC management

12 May 2021

Enzalutamide improves overall survival and delays metastasis in patients with nonmetastatic, castration-resistant prostate cancer: A local case review

22 Nov 2020

A case sharing of apalutamide in the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC) in Hong Kong

30 Oct 2019
Expert Insight View All

Redefining the management of non-muscle-invasive bladder cancer in one swoop with en bloc resection over standard transurethral resection

Bladder cancer is one of the most prevalent cancers worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases. While the standard piecemeal transurethral resection of bladder tumor (SR) has been the conventional surgical procedure for NMIBC, oncological control remains subpar, prompting the development of alternative techniques such as en bloc transurethral resection of bladder tumor (ERBT). To examine the impact of ERBT on the prognosis of NMIBC, Professor Teoh, Yuen-Chun Jeremy and his team conducted a local phase 3 randomized controlled trial, EB-StaR, that compared the 1-year recurrence rate of NMIBC with ERBT to SR. In an interview with Omnihealth Practice, Prof. Teoh discussed the implications of the results and the future of ERBT implementation.
06 Aug 2024
thumb
Professor Teoh, Yuen-Chun Jeremy
Associate Professor,
Department of Surgery,
Faculty of Medicine,
The Chinese University of Hong Kong

Optimizing the diagnosis and management of prostate cancer in Hong Kong

Prostate cancer (PCa) has the highest reported incidence rate among common male cancers in Hong Kong during the past two decades.1 It is the fourth leading cause of cancer-related deaths among males in Hong Kong.

31 Dec 2019
thumb

Dr. Poon, Ming-Chun Darren

Honorary Consultant in Clinical Oncology,
Hong Kong Sanatorium & Hospital
Honorary Clinical Associate Professor,
The Chinese University of Hong Kong
Conference update View All
thumb

ASCO 2023

June 2-6, 2023 | Chicago, USA

Meeting Highlight View All

The PROfound promise of genomics in mCRPC management

ONCOLOGY UROLOGY
12 May 2021
thumb

Dr. Joaquin Mateo

Medical Oncologist and Attending Physician,
Vall d’Hebron University Hospital, Barcelona
Principal Investigator,
Prostate Cancer Translational Research Group,
Vall d’Hebron Institute of Oncology
Research spotlight View All

Enhancing overactive bladder care: Expert consensus statements for Hong Kong clinicians

Overactive bladder (OAB) is a prevalent condition characterized by urinary urgency, often accompanied by increased frequency and nocturia, affecting a significant portion of the population.1 In Hong Kong, a survey indicated an age-adjusted prevalence of OAB at 15.1%, highlighting the need for effective management strategies tailored to the local context.1 The condition can severely impact the quality of life, necessitating a comprehensive approach to diagnosis and treatment.1
18 Dec 2024
Case review View All

Local case sharing: Benefits of early intensification with enzalutamide in mHSPC patients with high volume of disease

The advent of novel strategies has shifted the treatment paradigm of metastatic hormone-sensitive prostate cancer (mHSPC) from androgen deprivation therapy (ADT) monotherapy to combination therapies.1 Upfront addition of chemotherapy or androgen receptor (AR) inhibitors to ADT has demonstrated an improved overall survival (OS) and become a new standard of care (SoC) in this therapeutic area.2 The early treatment intensification is particularly important and beneficial to mHSPC patients with high volume of disease.3,4 In an interview with Omnihealth Practice,  Dr. Lee, Siu-Hong discussed the unmet needs in mHSPC, emphasizing the importance of using combination therapy for the high-volume patients. He also stressed the significance of monitoring prostate-specific antigen (PSA) response and shared a clinical case of a 70-year-old male diagnosed with de novo mHSPC with high volume of disease who was managed with upfront ADT + enzalutamide, then achieving a rapid reduction in the serum PSA levels. 
05 May 2023
thumb

Dr. Lee, Siu-Hong

Specialist in Clinical Oncology
News & perspective View All

Benign prostatic hyperplasia patients have a higher risk of urological complications after COVID-19 infection

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative organism of coronavirus disease 2019 (COVID-19), can also affect many extra-respiratory systems.1 As viral entry into host cells is facilitated by the interaction between the SARS-CoV-2 spike and angiotensin-converting enzym
09 May 2024

Multicomponent intervention including CBT improves QoL in women with overactive bladder

Overactive bladder (OAB) is a chronic condition characterized by urinary urgency, frequency, and nocturia, with or without urgency incontinence.1,2 It is estimated to affect 10%-20% of women, with higher incidence and more severe symptoms observed among older individuals.1,2 Behavioral therapy encom
09 May 2024